EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study

А Е Karateev iD, Е Y Polishchuk iD, Е S Filatova iD, V N Amirdzhanova iD, V N Khlaboshina iD, А М Lila iD, A A Baranov iD, N A Lapkina iD, G A Togizbayev iD

International Journal of Rheumatic Diseases · 2024

DOI: 10.1111/1756-185x.15320 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2024. Verfasst von А Е Karateev und 8 weiteren Autor:innen. Beteiligte Einrichtung: V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Pain Measurement, Chronic Pain, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSC R-Pharm, Russia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real‐world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.

Methods

An open‐label observational non‐interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow‐up period was 24 weeks or less. RA activity (DAS28‐CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT‐F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.

Results

The study cohort was comprised of 144 patients. And 39 patients were lost to follow‐up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28‐CRP decreased to 3.3 ± 0.9 ( p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration ( p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% ( p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% ( р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.

Conclusion

OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPain MeasurementChronic PainAntirheumatic AgentsHumansFemaleMaleMiddle AgedTreatment OutcomeAgedTime FactorsAntibodies, Monoclonal, HumanizedAdultMethotrexateSeverity of Illness IndexDrug Therapy, CombinationPatient Reported Outcome Measures

Stichwörter der Autor:innen

central sensitizationchronic painefficacyolokizumabrheumatoid arthritissafety

Substanzen

Antirheumatic AgentsAntibodies, Monoclonal, HumanizedMethotrexate

Autor:innen und Institutionen

  • V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation.
  • Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation.
  • Yaroslavl State Medical University, Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation.
  • Department of Rheumatology, Kazakh National Medical University named after Asfendiyarov S, Almaty, Russian Federation.

ORCID-Profile: А Е Karateev, Е Y Polishchuk, Е S Filatova, V N Amirdzhanova, V N Khlaboshina, А М Lila, A A Baranov, N A Lapkina, G A Togizbayev

Förderung

  • JSC R-Pharm, Russia

Zitieren

APA

Karateev, А. Е., Polishchuk, Е. Y., Filatova, Е. S., Amirdzhanova, V. N., Khlaboshina, V. N., Lila, А. М., Baranov, A. A., Lapkina, N. A., & Togizbayev, G. A. (2024). Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.15320

Vancouver

Karateev АЕ, Polishchuk ЕY, Filatova ЕS, Amirdzhanova VN, Khlaboshina VN, Lila АМ, et al. Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. International Journal of Rheumatic Diseases. 2024. doi:10.1111/1756-185x.15320

BibTeX
@article{Karateev2024,
  author = {Karateev, А Е and Polishchuk, Е Y and Filatova, Е S and Amirdzhanova, V N and Khlaboshina, V N and Lila, А М and Baranov, A A and Lapkina, N A and Togizbayev, G A},
  title = {Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2024},
  doi = {10.1111/1756-185x.15320}
}
Kostenlos starten →